RT Journal Article
SR Electronic
T1 Lineage BA.2 dominated the Omicron SARS-CoV-2 epidemic wave in the Philippines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.30.22275783
DO 10.1101/2022.05.30.22275783
A1 Li, Yao-Tsun
A1 Polotan, Francisco Gerardo M.
A1 Sotelo, Gerald Ivan S.
A1 Alpino, Anne Pauline A.
A1 Dolor, Ardiane Ysabelle M.
A1 Tujan, Ma. Angelica A.
A1 Gomez, Ma. Ricci R.
A1 Onza, Othoniel Jan T.
A1 Chang, Angela Kae T.
A1 Bautista, Criselda T.
A1 Carandang, June C.
A1 Lim, Dodge R.
A1 Dancel, Lei Lanna M.
A1 Uy-Lumandas, Mayan
A1 Dizon, Timothy John R.
A1 Hampson, Katie
A1 Daldry, Simon
A1 Hughes, Joseph
A1 Brunker, Kirstyn
YR 2022
UL http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275783.abstract
AB The Omicron SARS-CoV-2 variant led to a dramatic global epidemic wave following detection in South Africa in November, 2021. The Omicron lineage BA.1 was dominant and responsible for most domestic outbreaks during December 2021-January 2022, whilst other Omicron lineages including BA.2 accounted for the minority of global isolates. Here, we describe the Omicron wave in the Philippines by analysing genomic data. Our results identify the presence of both BA.1 and BA.2 lineages in the Philippines in December 2021, before cases surged in January 2022. We infer that only lineage BA.2 underwent sustained transmission in the country, with an estimated emergence around November 18th, 2021 [95% highest posterior density: November 6-28th], whilst despite multiple introductions BA.1 transmission remained limited. These results suggest the Philippines was one of the earliest areas affected by BA.2, and reiterate the importance of whole-genome sequencing for monitoring outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by the UK Research and Innovation Global effort on COVID-19 (MR/V035444/1) and Wellcome (207569/Z/17/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the Institutional Review Board of Research Institute of Tropical Medicine, Department of Health, Philippines (IRB Number: 2020-38-2).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data collected by the GECO project are available on GISAID, and accession numbers of the sequences analysed in this study have been compiled as an EPI SET (EPI_SET_20220430vo). The XML file required for BEAST, details of genetic analyses including phylogenetic trees are available at https://github.com/GECO-PH/GECO-covid/tree/main/manuscript_BA2.